Home | All trials

[RDF data]
Trial NCT00000634

Resource URI: http://static.linkedct.org/resource/trials/NCT00000634
PropertyValue
linkedct:brief_title A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/887>
linkedct:condition <http://static.linkedct.org/resource/condition/5486>
linkedct:criteria Inclusion Criteria Concurrent Medication: Allowed: - Intravenous gammaglobulin. Pneumocystis prophylaxis according to published guidelines. Patients must have the following: - HIV infection. - Parent or guardian must be available to give written informed consent. Exclusion Criteria Concurrent Medication: Excluded: - Zidovudine (AZT). - Steroid dependency. Excluded within 1 hour before and 4 hours after study drug administration: - Drugs that might interfere with the absorption of study drug (H2 blockers, antacids, carafate, cholestyramine). - Benzodiazepines. - Alcohol-containing substances. Concurrent Treatment: Excluded: - Requiring supplemental oxygen. Patients with the following are excluded: - Active opportunistic or serious bacterial infection. - Lymphoid interstitial pneumonitis (LIP) and steroid dependent or requiring supplemental oxygen or have a pretreatment pa02 < 70 mm Hg. - Pre-existing malignancies. Prior Medication: Excluded: - Zidovudine (AZT) within 7 days prior to administration of study drug. Excluded for at least 4 weeks prior to drug administration: - Other approved or investigational antiretroviral agents. All other investigational agents. Biologic response modifiers (e.g., interferon) or immunomodulators. Immunosuppressive agents (including glucocorticoids). Coumadin and other anticoagulant medications. Prior Treatment: Excluded: - Red blood cell transfusion within 4 weeks of study entry. Patients may not have the following: - Opportunistic or serious bacterial infection. Zidovudine (AZT) > 7 days prior to administration of study drug. Active alcohol or drug abuse.
linkedct:description Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects. Two doses, given by mouth, are evaluated: Three patients receive the lower dose, and 7 days after the third patient receives the lower dose, three additional patients receive the higher dose. After dosing, blood is drawn at 1, 2, 4, 8, 24, 48, 96, 168 hours to measure blood levels of the drug.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 13 Years
linkedct:eligibility_minimum_age 2 Months
linkedct:enrollment 6 (xsd:int)
linkedct:firstreceived_date November 2, 1999
linkedct:id NCT00000634
rdfs:label Trial NCT00000634
linkedct:lastchanged_date August 20, 2008
linkedct:lead_sponsor_agency National Institute of Allergy and Infectious Diseases (NIAID)
linkedct:location <http://static.linkedct.org/resource/location/146932>
linkedct:nct_id NCT00000634
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
linkedct:org_study_id ACTG 165
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000634>
linkedct:phase N/A
linkedct:reference <http://static.linkedct.org/resource/reference/50731>
linkedct:secondary_id 00853
linkedct:source National Institute of Allergy and Infectious Diseases (NIAID)
linkedct:study_design Treatment, Dose Comparison, Safety Study
linkedct:study_type Interventional
linkedct:summary To generate initial information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess the safety and tolerance of single rising oral doses of nevirapine in HIV-infected children; and to confirm that the single doses that achieve certain plasma levels in adults achieve similar levels in HIV-infected children. Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects.
rdf:type linkedct:trials
linkedct:verification_date April 1996